World leader in diagnostic and therapeutic imaging products selects Global 2.0 to manage its medical devices approvals and submissions worldwide.
Framingham, MA, December 28, 2005 – clinivation, Inc. announced today that MEDRAD, Inc. has selected clinivation Global™ 2.0 software.
“MEDRAD’s world-class operations have been awarded top honors for quality-systems and business excellence,” said Joseph Kozikowski, M.D., clinivation’s Chief Executive Officer. “We are especially pleased that MEDRAD’s quality-committed organization has selected clinivation Global 2.0 to integrate into their award-winning quality systems and operations,” he continued.
Clinivation Global 2.0 software enables medical device companies to sell more products to more countries faster and easier than ever before. Global 2.0 is the first complete solution targeted at automating the business processes for medical device approvals worldwide.
About MEDRAD, INC.
MEDRAD, Inc. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD’s product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2004 revenues were $343 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company’s world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a U.S. affiliate of Schering AG, Germany (FSE:SCH; NYSE:SHR).
Visit MEDRAD, Inc. online at www.medrad.com